Outcome and Summary of the 14th Annual General Meeting held on 30th August, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dipna Pharmachem Limited held its 14th Annual General Meeting on 30th August 2025 via video conferencing, lasting only 6 minutes from 4:02 PM to 4:08 PM. The meeting, chaired by Director Mrs. Dipna Shah, covered seven resolutions including adoption of audited financial statements for FY ended 31st March 2025 and re-appointment of Mr. Nirav Soni as director (retiring by rotation). A special resolution was tabled to appoint Mr. Parin Bhavsar as a Non-Executive and Independent Director. Three ordinary resolutions sought shareholder approval for related party transactions with Dhara Pharmachem Private Limited, Dipan Pharmachem Private Limited, and Cedac Medicorp. Additionally, shareholders were asked to approve an increase in the company's authorised share capital and a corresponding amendment to the Capital clause of the Memorandum of Association.
Shareholders should watch for the e-voting results within two working days, which will confirm whether these proposals — particularly the capital expansion and related party deals — have been approved. Approval of a higher authorised share capital gives the company flexibility to raise fresh funds or issue shares in the future, while multiple related party transactions warrant a close look at terms to ensure arm's-length pricing.